m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00363)
Name
5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide
Synonyms
CHEMBL84288
    Click to Show/Hide
Status
Investigative
Structure
Formula
C11H14ClNO2
InChI
1S/C11H14ClNO2/c12-10-7-5-9(6-8-10)3-1-2-4-11(14)13-15/h5-8,15H,1-4H2,(H,13,14)
InChIKey
PRMXJXDYJXBBPT-UHFFFAOYSA-N
PubChem CID
11528707
TTD Drug ID
D0V2ZO
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Histone deacetylase 2 (HDAC2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Histone deacetylase 2 (HDAC2) is a therapeutic target for 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide through regulating the expression of Histone deacetylase 2 (HDAC2). [1], [2]
References
Ref 1 The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018 Feb;52(2):621-629. doi: 10.3892/ijo.2017.4219. Epub 2017 Dec 7.
Ref 2 Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. doi: 10.1021/jm015568c.